In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests

Executive Summary

The availability of novel assay platforms represents a tipping point for diagnostics' adoption in the markets for translational medicine, esoteric testing, and high-complexity labs. Platform companies may be accustomed to defining their business strategies in terms of maximizing instrument placements but this may not be the optimal path to commercial success for a novel diagnostic test. They need to develop "category-killer" tests--those that combine platform and diagnostic content to offer a compelling clinical value proposition.

You may also be interested in...



Delivering Cancer Diagnostics Tools

Pharma is keenly interested in new cancer diagnostics tools, which in many cases are aimed at selecting the best therapy for a specific patient, measuring response to therapy and predicting or more sensitively measuring relapse. These technologies are often the same as those used in pharma's drug development efforts. But deciding with whom and how to ally for the development and distribution of tests is difficult, showing just how uncharted, and bumpy, is the current diagnostics terrain.

Nanostring Unveils Its Molecular Diagnostics Strategy

One strategy for growth among analytical platform companies is to leverage its instrumentation sales channel by developing or acquiring diagnostics content. Nanostring is now doing this by in-licensing a gene expression signature for breast tumor typing. And unlike other molecular tests for guiding breast cancer therapy, which are performed in specialty CLIA labs run by their developers, this one will be broadly distributed to hospitals and pathology laboratories globally.

Nanostring Unveils Its Molecular Diagnostics Strategy

One strategy for growth among analytical platform companies is to leverage its instrumentation sales channel by developing or acquiring diagnostics content. Nanostring is now doing this by in-licensing a gene expression signature for breast tumor typing. And unlike other molecular tests for guiding breast cancer therapy, which are performed in specialty CLIA labs run by their developers, this one will be broadly distributed to hospitals and pathology laboratories globally.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel